About Prometheus Biosciences
Prometheus Biosciences is a company based in San Diego (United States) founded in 2016 by Stephan Targan was acquired by Merck in April 2023. Prometheus Biosciences has raised $130 million across 1 funding round from investors including Merck, Nestlé and Cedars Sinai. Prometheus Biosciences operates in a competitive market with competitors including Aclaris Therapeutics, Protagonist Therapeutics, OMass Therapeutics, Enterome and CytoKi Pharma, among others.
- Headquarter San Diego, United States
- Founders Stephan Targan
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Prometheus Biosciences
Unlock access to complete
Unlock access to complete
Leadership Team
442 people
Software Development Team
251 people
Product Management Team
73 people
Sales and Marketing
73 people
Senior Team
64 people
Data Analysis and Operations Team
63 people
Operations Team
54 people
Finance and Accounting
30 people
Unlock access to complete
Funding Insights of Prometheus Biosciences
Prometheus Biosciences has successfully raised a total of $130M through 1 strategic funding round. The most recent funding activity was a Series D round of $130 million completed in November 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Prometheus Biosciences
Prometheus Biosciences has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include Merck, Nestlé and Cedars Sinai.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life Sciences focused VC firm investing in the US
|
Locked | Locked | Locked | |
|
Health-tech companies are targeted for venture capital investments.
|
Locked | Locked | Locked | |
|
Early-stage startups are invested in by sector-agnostic VC fund.
|
Locked | Locked | Locked |
Investor details for Prometheus Biosciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Prometheus Biosciences
Investment portfolio details for Prometheus Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Prometheus Biosciences
Detailed financials for Prometheus Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Prometheus Biosciences Comparisons
Peer comparison for Prometheus Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Prometheus Biosciences
Prometheus Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aclaris Therapeutics, Protagonist Therapeutics, OMass Therapeutics, Enterome and CytoKi Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel dermatologic therapies are developed for skin conditions.
|
|
| Locked | Locked | Locked |
Oral peptide therapeutics are developed for gastrointestinal diseases.
|
|
| Locked | Locked | Locked |
Proprietary mass spectrometry technologies are developed for protein assembly analysis.
|
|
| Locked | Locked | Locked |
Developer of immunomodulators for cancer and auto-immune diseases
|
|
| Locked | Locked | Locked |
Therapeutics for epithelial-based diseases are developed and targeted.
|
Detailed competitors of Prometheus Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Prometheus Biosciences
Complete news archive for Prometheus Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Prometheus Biosciences
Prometheus Biosciences was founded in 2016 and raised its 1st funding round 4 years after it was founded.
Prometheus Biosciences is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Prometheus Biosciences is a funded company, having raised a total of $130M across 1 funding round to date.
Prometheus Biosciences was founded in 2016 in San Diego, United States, within the biotechnology sector. Treatments for gastrointestinal diseases, especially bowel-related conditions, are developed through a clinical biobank that includes medical records. Targets for biomarker-defined subclinical GI phenotypes are identified using this resource. Pipeline products are advanced through clinical trial phases to address patient needs in this area.
Prometheus Biosciences's top competitors include Aclaris Therapeutics, Protagonist Therapeutics and Samsung Bioepis.
Prometheus Biosciences has 11 investors. Key investors include Merck, Nestlé, Cedars Sinai, TD Securities, and RTW Investments.